Georgia State University

ScholarWorks @ Georgia State University
GHPC Articles

Georgia Health Policy Center

12-1-2013

Georgia Phresh Findings: Contributions to Surveillance by Dataset
Georgia Health Policy Center

Follow this and additional works at: https://scholarworks.gsu.edu/ghpc_articles

Recommended Citation
Georgia Health Policy Center, "Georgia Phresh Findings: Contributions to Surveillance by Dataset" (2013).
GHPC Articles. 108.
https://scholarworks.gsu.edu/ghpc_articles/108

This Article is brought to you for free and open access by the Georgia Health Policy Center at ScholarWorks @
Georgia State University. It has been accepted for inclusion in GHPC Articles by an authorized administrator of
ScholarWorks @ Georgia State University. For more information, please contact scholarworks@gsu.edu.

Georgia

PHRESH Findings

Public Health Research Evaluation and Surveillance for Hemoglobinopathies

December 2013

Contributions to Surveillance by Dataset
The first priority of the Registry and Surveillance for Hemoglobinopathies (RuSH) project was to determine the number
of people with sickle cell disease living in Georgia during the five-year period, 2004-2008. To identify cases, we used data
from seven sources: Georgia’s Newborn Screening program; the comprehensive sickle cell centers at Georgia Regents
University (GRU), Grady Health System, and Children’s Healthcare of Atlanta (CHOA); and administrative claims data
from Georgia’s Medicaid/CHIP program, State Health Benefit Plan (SHBP), and the Georgia Hospital Association (GHA).
Datasets were examined individually to identify cases, which were then matched against those identified from other
sources for de-duplication and linking. This entailed numerous iterations and matching algorithms. Using CDC’s RuSH
case definition, we classified cases as Level 1 (confirmed), Level 2 (probable), or Level 3 (possible) sickle cell disease. The
table below summarizes our results.
Sickle Cell Cases in Georgia Identified through RuSH, 2004-2008
Data Set

Level 1

Level 2

Level 3

Level 1,2,3

730

98

0

828

GRU (clinic)

1,218

14

0

1,232

Grady (clinic)

1,661

2

0

1,663

CHOA (clinic)

1,908

242

427

2,577

Medicaid/CHIP

2,986

1,993

6,510

11,489

209

215

598

1,022

Hosptial administrative data

3,339

2,147

3,230

8,716

De-duplicated Total

4,288

3,011

*9,208

16,507

Newborn Screening

State Health Benefit Plan

*Plus 77 vital records with an ICD-10 code of D57 included as an underlying cause of death.
Georgia requires all babies born in the state to be screened for sickle cell disease. Those with positive screening results are
contacted for confirmatory testing. Eighty-eight percent of the 828 newborns who screened positive for sickle cell disease
from 2004-2008 had a documented confirmatory diagnosis. These 730 newborns met the Level 1 case definition; while 98
with positive screens but no confirmatory test were categorized as Level 2. Case matching revealed that roughly 80 percent
of newborns who screened positive for sickle cell disease were later seen at one of Georgia’s two pediatric sickle cell centers.
The comprehensive sickle cell centers contributed the remainder of the Level 1 cases. Using patient registry data,
Grady and GRU contributed 1,661 and 1,218 confirmed cases respectively. Additionally, Grady contributed 2 and GRU
contributed 14 Level 2 cases of sickle cell disease with an unknown genotype. Using administrative data augmented by
lab and patient records, CHOA identified 1,908 Level 1 cases. The remaining 242 Level 2 and 427 Level 3 cases came from
administrative data collected from CHOA’s clinic and hospital sites.
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Whereas the data sources described thus far provide excellent clinical
and diagnostic information, administrative datasets offer abundant
information on health care utilization, but less certainty regarding
diagnosis. The Medicaid/CHIP, SHBP, and hospital discharge data alone
can only add new cases in Levels 2 and 3. The final matched, merged,
and de-duplicated dataset is rich with both diagnostic and health care
utilization data, as roughly 70 percent of the 4,288 Level 1 cases were
found in Medicaid/CHIP claims data; 78 percent in hospital/ER discharge
data; and 5 percent in SHBP data.
The Medicaid/CHIP dataset added the largest number of Level 2 and
3 cases (1,993 and 6,510, respectively). To meet the Level 2 definition,
cases must show repeated sickle cell disease diagnostic codes as well as
health care utilization consistent with the disease. The Level 3 definition
has a lower standard, including codes for sickle cell trait and health care
utilization consistent with sickle cell disease. It is likely that most Level 3
cases indeed are sickle cell trait rather than disease, although there could
be some miscoded cases here as well.
Hospital/ER discharge data added 2,147 Level 2 cases and 3,230 Level 3
cases to the surveillance dataset. Of Level 2 additions, 765 did not overlap
with Medicaid/CHIP or SHBP, likely representing individuals who had
emergency or inpatient encounters during the study period and were
either uninsured or had private insurance or Medicare.
The SHBP data contributed another 215 Level 2 cases and 598 Level 3 cases. SHBP is this project’s only source of health
care utilization data for privately insured patients. As the state is one of the largest employers in Georgia with more
than 600,000 covered lives in 2008, this data represents approximately 11 percent of the state’s privately insured. From
a comparison of SHBP to Medicaid/CHIP cases and a separate analysis of our Hospital/ER discharge data by payer, we
estimate that close to two-thirds of those with sickle cell disease in Georgia received public coverage at some point during
the study period.
In total, we identified 4,288 confirmed and 3,011 probable cases of sickle cell disease in Georgia from 2004-2008.
This is consistent with previous estimates for Georgia, which range from 4,981 to 8,427 depending on the method of
approximation.1 Linking data from our seven sources, we found an additional 9,208 cases categorized as possible sickle cell
disease.
Georgia is extending RuSH efforts through the Public Health Research, Epidemiology, and Surveillance of
Hemoglobinopathies (PHRESH) project by performing validation studies of the CDC case definition and examining the
use of prevention strategies recommended for sickle cell patients. These investigations are possible using our unique dataset
that links health care utilization variables to cases with confirmed sickle cell disease diagnosis.
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